Imperial College London

ProfessorPatrickSerruys

Faculty of MedicineNational Heart & Lung Institute

Visiting Professor
 
 
 
//

Contact

 

p.serruys

 
 
//

Location

 

c/o Prof Kim FoxGuy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Gogas:2013:10.4244/EIJV9I6A115,
author = {Gogas, BD and Bourantas, CV and Garcia-Garcia, HM and Onuma, Y and Muramatsu, T and Farooq, V and Diletti, R and van, Geuns R-JM and De, Bruyne B and Chevalier, B and Thuesen, L and Smits, PC and Dudek, D and Koolen, J and Windecker, S and Whitbourn, R and McClean, D and Dorange, C and Miquel-Hebert, K and Veldhof, S and Rapoza, R and Ormiston, JA and Serruys, PW},
doi = {10.4244/EIJV9I6A115},
journal = {EuroIntervention},
pages = {709--720},
title = {The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials.},
url = {http://dx.doi.org/10.4244/EIJV9I6A115},
volume = {9},
year = {2013}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - AIMS: To assess serially the edge vascular response (EVR) of a bioresorbable vascular scaffold (BVS) compared to a metallic everolimus-eluting stent (EES). METHODS AND RESULTS: Non-serial evaluations of the Absorb BVS at one year have previously demonstrated proximal edge constrictive remodelling and distal edge changes in plaque composition with increase of the percent fibro-fatty (FF) tissue component. The 5 mm proximal and distal segments adjacent to the implanted devices were investigated serially with intravascular ultrasound (IVUS), post procedure, at six months and at two years, from the ABSORB Cohort B1 (n=45) and the SPIRIT II (n=113) trials. Twenty-two proximal and twenty-four distal edge segments were available for analysis in the ABSORB Cohort B1 trial. In the SPIRIT II trial, thirty-three proximal and forty-six distal edge segments were analysed. At the 5-mm proximal edge, the vessels treated with an Absorb BVS from post procedure to two years demonstrated a lumen loss (LL) of 6.68% (-17.33; 2.08) (p=0.027) with a trend toward plaque area increase of 7.55% (-4.68; 27.11) (p=0.06). At the 5-mm distal edge no major changes were evident at either time point. At the 5-mm proximal edge the vessels treated with a XIENCE V EES from post procedure to two years did not show any signs of LL, only plaque area decrease of 6.90% (-17.86; 4.23) (p=0.035). At the distal edge no major changes were evident with regard to either lumen area or vessel remodelling at the same time point. CONCLUSIONS: The IVUS-based serial evaluation of the EVR up to two years following implantation of a bioresorbable everolimus-eluting scaffold shows a statistically significant proximal edge LL; however, this finding did not seem to have any clinical implications in the serial assessment. The upcoming imaging follow-up of the Absorb BVS at three years is anticipated to provide further information regarding the vessel wall behaviour at the edges.
AU - Gogas,BD
AU - Bourantas,CV
AU - Garcia-Garcia,HM
AU - Onuma,Y
AU - Muramatsu,T
AU - Farooq,V
AU - Diletti,R
AU - van,Geuns R-JM
AU - De,Bruyne B
AU - Chevalier,B
AU - Thuesen,L
AU - Smits,PC
AU - Dudek,D
AU - Koolen,J
AU - Windecker,S
AU - Whitbourn,R
AU - McClean,D
AU - Dorange,C
AU - Miquel-Hebert,K
AU - Veldhof,S
AU - Rapoza,R
AU - Ormiston,JA
AU - Serruys,PW
DO - 10.4244/EIJV9I6A115
EP - 720
PY - 2013///
SP - 709
TI - The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials.
T2 - EuroIntervention
UR - http://dx.doi.org/10.4244/EIJV9I6A115
UR - https://www.ncbi.nlm.nih.gov/pubmed/23628499
VL - 9
ER -